Previous close | 0.0470 |
Open | 0.0470 |
Bid | 0.0400 x N/A |
Ask | 0.0480 x N/A |
Day's range | 0.0460 - 0.0470 |
52-week range | 0.0400 - 0.1550 |
Volume | |
Avg. volume | 190,088 |
Market cap | N/A |
Beta (5Y monthly) | 2.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0050 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay and CMO Dr Dana Hilt will present at the BIO International Convention, to be held at the Boston Convention & Exhibition Center from June 5-8, 2023. The Actinogen presentation is scheduled at 4pm EST Monday June 5, in Room 403.
Actinogen Medical ASX: ACW ("ACW" or "the Company") is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (ADPD™ 2023) later today in Gothenburg, Sweden.
Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2b, placebo-controlled clinical trial of Xanamem in patients with early stages of Alzheimer's Disease (AD).
Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression clinical trial that will measure the effects of Xanamem on safety, cognitive performance and depression in patients who are inadequately treated by their anti-depressant medication and have both depressive symptoms and cognitive impairment.
Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alzheimer's Disease (AD) biomarker study, which validates the Company's planned Xanamem program in AD.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...